Bionomics’ Half-Year Report
23 févr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
Quarterly Activities and Cashflow Report
30 janv. 2023 18h23 HE
|
Bionomics Ltd
ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
18 déc. 2022 19h34 HE
|
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
15 déc. 2022 18h35 HE
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
02 déc. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
21 nov. 2022 18h13 HE
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
16 nov. 2022 18h36 HE
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
Bionomics Limited to Participate in Upcoming November Investor Conferences
02 nov. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Quarterly Activities Report for September 2022
25 oct. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
18 oct. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the...